Real‐Life Cohort of Patients With Resected High‐Risk Melanoma Treated by Adjuvant Anti‐PD1 Therapy
ABSTRACT Background Programmed cell death protein‐1 (PD1) antibodies are currently the standard treatment for resected high‐risk melanoma, yet recurrence rate remains high. Objectives This real‐life observational study aimed to describe the outcomes of patients with resected high‐risk melanoma follo...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-03-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70432 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850200553160704000 |
|---|---|
| author | Liza Benzoni Anaïs Eberhardt Sarah Milley Safa Idoudi Camille Trefcon Nicolas Romain‐Scelle Luc Thomas Stéphane Dalle |
| author_facet | Liza Benzoni Anaïs Eberhardt Sarah Milley Safa Idoudi Camille Trefcon Nicolas Romain‐Scelle Luc Thomas Stéphane Dalle |
| author_sort | Liza Benzoni |
| collection | DOAJ |
| description | ABSTRACT Background Programmed cell death protein‐1 (PD1) antibodies are currently the standard treatment for resected high‐risk melanoma, yet recurrence rate remains high. Objectives This real‐life observational study aimed to describe the outcomes of patients with resected high‐risk melanoma following adjuvant anti‐PD1 immunotherapy and identify factors associated with recurrence risk. Materials and Methods A total of 235 patients with resected stage III/IV melanoma treated with adjuvant nivolumab or pembrolizumab were included. Imaging scans and cerebral imaging were performed every 12 weeks to detect recurrences. Adverse events were collected. Univariate and multivariate analyses were performed to identify predictive factors of recurrence. Overall survival (OS) and recurrence‐free survival (RFS) were estimated. Results Among the 235 patients, 103 experienced at least one recurrence (43%); first recurrences were predominantly locoregional (47%). The predictive factor for recurrence identified by multivariate analysis was ulceration (RR 2,03, 95% CI [1,20; 2,86]). RFS was estimated at 75% [70–81] at 12 months and at 64% [58–71] at 24 months. RFS at 12 months was significantly lower in patients with ulcerations (RFS at 83%) compared to those without ulceration (RFS at 66%), p < 0.01. Overall survival (OS) was estimated at 91% [87%–94%] at 12 months and 84% [79%–89%] at 24 months. The OS after a first recurrence was estimated at 69% [60%–80%] at 12 months and decreased to 43% [32%–57%] at 24 months. After a first locoregional recurrence, surgery with a year of adjuvant immunotherapy (40%) was the favoured therapeutic approach. For distant recurrences, clinical trial enrolment was preferred (21%). Double curative immunotherapy was the preferred strategy for cerebral recurrences (30%). Conclusions In this cohort, nearly half of the patients underwent recurrences and RFS at 24 months was 64%. The RFS and OS data were comparable o those reported in the pivotal study Ulceration was the only significant predictive factor for recurrence, associated with decreased RFS at 24 months. |
| format | Article |
| id | doaj-art-22dc7b74374648c7bafb980bc40b6d55 |
| institution | OA Journals |
| issn | 2045-7634 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-22dc7b74374648c7bafb980bc40b6d552025-08-20T02:12:19ZengWileyCancer Medicine2045-76342025-03-01146n/an/a10.1002/cam4.70432Real‐Life Cohort of Patients With Resected High‐Risk Melanoma Treated by Adjuvant Anti‐PD1 TherapyLiza Benzoni0Anaïs Eberhardt1Sarah Milley2Safa Idoudi3Camille Trefcon4Nicolas Romain‐Scelle5Luc Thomas6Stéphane Dalle7Service de Dermatologie, Hospices Civils de Lyon Hôpital Lyon Sud Lyon FranceService de Dermatologie, Hospices Civils de Lyon Hôpital Lyon Sud Lyon FranceService de Dermatologie, Hospices Civils de Lyon Hôpital Lyon Sud Lyon FranceService de Dermatologie, Hôpital Saint Louis Paris FranceService de Dermatologie, Hospices Civils de Lyon Hôpital Lyon Sud Lyon FranceService de Biostatistique, Hospices Civils de Lyon Hôpital Lyon Sud Pierre‐Bénite FranceService de Dermatologie, Hospices Civils de Lyon Hôpital Lyon Sud Lyon FranceService de Dermatologie, Hospices Civils de Lyon Hôpital Lyon Sud Lyon FranceABSTRACT Background Programmed cell death protein‐1 (PD1) antibodies are currently the standard treatment for resected high‐risk melanoma, yet recurrence rate remains high. Objectives This real‐life observational study aimed to describe the outcomes of patients with resected high‐risk melanoma following adjuvant anti‐PD1 immunotherapy and identify factors associated with recurrence risk. Materials and Methods A total of 235 patients with resected stage III/IV melanoma treated with adjuvant nivolumab or pembrolizumab were included. Imaging scans and cerebral imaging were performed every 12 weeks to detect recurrences. Adverse events were collected. Univariate and multivariate analyses were performed to identify predictive factors of recurrence. Overall survival (OS) and recurrence‐free survival (RFS) were estimated. Results Among the 235 patients, 103 experienced at least one recurrence (43%); first recurrences were predominantly locoregional (47%). The predictive factor for recurrence identified by multivariate analysis was ulceration (RR 2,03, 95% CI [1,20; 2,86]). RFS was estimated at 75% [70–81] at 12 months and at 64% [58–71] at 24 months. RFS at 12 months was significantly lower in patients with ulcerations (RFS at 83%) compared to those without ulceration (RFS at 66%), p < 0.01. Overall survival (OS) was estimated at 91% [87%–94%] at 12 months and 84% [79%–89%] at 24 months. The OS after a first recurrence was estimated at 69% [60%–80%] at 12 months and decreased to 43% [32%–57%] at 24 months. After a first locoregional recurrence, surgery with a year of adjuvant immunotherapy (40%) was the favoured therapeutic approach. For distant recurrences, clinical trial enrolment was preferred (21%). Double curative immunotherapy was the preferred strategy for cerebral recurrences (30%). Conclusions In this cohort, nearly half of the patients underwent recurrences and RFS at 24 months was 64%. The RFS and OS data were comparable o those reported in the pivotal study Ulceration was the only significant predictive factor for recurrence, associated with decreased RFS at 24 months.https://doi.org/10.1002/cam4.70432adjuvantanti‐PD1 therapyhigh‐risk melanoma |
| spellingShingle | Liza Benzoni Anaïs Eberhardt Sarah Milley Safa Idoudi Camille Trefcon Nicolas Romain‐Scelle Luc Thomas Stéphane Dalle Real‐Life Cohort of Patients With Resected High‐Risk Melanoma Treated by Adjuvant Anti‐PD1 Therapy Cancer Medicine adjuvant anti‐PD1 therapy high‐risk melanoma |
| title | Real‐Life Cohort of Patients With Resected High‐Risk Melanoma Treated by Adjuvant Anti‐PD1 Therapy |
| title_full | Real‐Life Cohort of Patients With Resected High‐Risk Melanoma Treated by Adjuvant Anti‐PD1 Therapy |
| title_fullStr | Real‐Life Cohort of Patients With Resected High‐Risk Melanoma Treated by Adjuvant Anti‐PD1 Therapy |
| title_full_unstemmed | Real‐Life Cohort of Patients With Resected High‐Risk Melanoma Treated by Adjuvant Anti‐PD1 Therapy |
| title_short | Real‐Life Cohort of Patients With Resected High‐Risk Melanoma Treated by Adjuvant Anti‐PD1 Therapy |
| title_sort | real life cohort of patients with resected high risk melanoma treated by adjuvant anti pd1 therapy |
| topic | adjuvant anti‐PD1 therapy high‐risk melanoma |
| url | https://doi.org/10.1002/cam4.70432 |
| work_keys_str_mv | AT lizabenzoni reallifecohortofpatientswithresectedhighriskmelanomatreatedbyadjuvantantipd1therapy AT anaiseberhardt reallifecohortofpatientswithresectedhighriskmelanomatreatedbyadjuvantantipd1therapy AT sarahmilley reallifecohortofpatientswithresectedhighriskmelanomatreatedbyadjuvantantipd1therapy AT safaidoudi reallifecohortofpatientswithresectedhighriskmelanomatreatedbyadjuvantantipd1therapy AT camilletrefcon reallifecohortofpatientswithresectedhighriskmelanomatreatedbyadjuvantantipd1therapy AT nicolasromainscelle reallifecohortofpatientswithresectedhighriskmelanomatreatedbyadjuvantantipd1therapy AT lucthomas reallifecohortofpatientswithresectedhighriskmelanomatreatedbyadjuvantantipd1therapy AT stephanedalle reallifecohortofpatientswithresectedhighriskmelanomatreatedbyadjuvantantipd1therapy |